Faron Pharmaceuticals Oy (â€Faronâ€), the clinical stage biopharmaceutical company, announced today it has entered into an agreement with Swiss-based Selexis SA. Under the agreement, Faron will have access to the Selexis SUREtechnology Platformâ„¢ and SURE CHO-M Cell Lineâ„¢ for the production of high-expressing and stable clonal cell lines for use in the development and production of Clevegen, its novel cancer immunotherapy antibody. Selexis SUREtechnology will enable the rapid generation of high expressing clonal cells for the production of monoclonal antibodies.…
Wednesday, November 4, 2015 Daily Archives
New ambr® 15 fermentation Micro Scale Bioreactor System Provides Enhanced Microbial Strain Screening with Fed-Batch Capability
Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, today introduced the new ambr® 15 fermentation system, an automated micro bioreactor system designed to enhance microbial strain screening with advanced capabilities supporting fed-batch microbial cultures. The new system, based on the gold-standard ambr 15 micro bioreactor technology, has been designed to meet the requirements of microbial fermentation. It comprises 24 single-use stirred micro bioreactors (each with an 8-12 mL working volume) integrated to a user-friendly, automated workstation.…